Impact of lanadelumab in hereditary angioedema: a case series of 12 patients in Canada

Allergy, Asthma & Clinical Immunology

Aled Iaboni¹  Christine Song²  Gina Lacuesta³  Amin Kanani⁴  Manstein Kan⁵  Stephen D. Betschel⁶ 

[1] Allergy/Immunology Fellow, Department of Internal Medicine, Division of Clinical Immunology and Allergy, University of Toronto, St. Michael’s Hospital, Toronto, ON, Canada;Department of Medicine, Division of Allergy and Immunology, St. Michael’s Hospital, University of Toronto, Toronto, ON, Canada;Department of Medicine, Nova Scotia Health Authority, Dalhousie University, Halifax, NS, Canada;Division of Allergy and Immunology, Department of Medicine, St. Paul’s Hospital, University of British Columbia, Vancouver, BC, Canada;Division of Allergy and Immunology, Department of Medicine, University of British Columbia, Vancouver, BC, Canada;Medicine and Departmental Division Director for Clinical Immunology and Allergy, Division of Clinical Immunology and Allergy, University of Toronto, St. Michael’s Hospital, Toronto, ON, Canada;

关键词: Lanadelumab;    Hereditary angioedema;    HAE;    Swelling;   

DOI  :  10.1186/s13223-021-00579-6

来源: Springer

【 摘 要 】

BackgroundHereditary angioedema (HAE) is a rare autosomal dominant disease resulting in recurring episodes of swelling, leading to considerable patient morbidity and mortality. Lanadelumab is a plasma kallikrein inhibitor that is approved as 1st line therapy in Canada for long term prophylaxis of HAE attacks.ObjectiveTo describe our clinical findings from a case series of adult patients with HAE type 1/2 who have been initiated on lanadelumab.MethodsA chart review of HAE type 1/2 patients at three academic centers in Canada was undertaken with demographic and clinical data extracted. Patients were included if they had been receiving lanadelumab for at least 6 months. Patients with other causes of angioedema were excluded.Results12 patients meeting enrollment criteria were identified. Compared to pre-lanadelumab, patients had mean reductions of 72% and 62% in attack rate and treated attack rate respectively. 3 patients reported complete remission from attacks after starting lanadelumab. Most patients had significant improvements in HAE impact on social outings.ConclusionOur case series findings support the 2019 International/Canadian HAE guideline that lanadelumab is an effective therapy for long term prophylaxis. In our patient population, initiation of lanadelumab improved disease control, minimized the burden of treatment and improved HAE impact on social outings.

【 授权许可】

CC BY